A study of coagulation profile in patients with cancer in a tertiary care hospital

Mirshahi S, Pritchard LL, Pocard M, Mirshahi M, Soria J. Pathogenesis and Diagnosis of Venous Hypercoagulable States in Cancer. J Hematol Thrombo Dis. 2015; 3: 3.

Chavez-MacGregor M, Zhao H, Kroll M, Fang S, Zhang N et al. Risk factors and incidence of thromboembolic events (TEEs) in older men and women with breast cancer. Ann Oncol. 2011; 22: 2394-2402. PubMed: https://pubmed.ncbi.nlm.nih.gov/21393379/

Kirwan CC, McDowell G, McCollum CN, Byrne GJ. Incidence of Venous Thromboembolism during Chemotherapy for Breast Cancer: Impact on Cancer Outcome. Anticnacer Res. 2011; 31: 2383-2388. PubMed: https://pubmed.ncbi.nlm.nih.gov/21737669/

Bremnes RM, Donnem T, Al-Saad S, Camps C, Marinez I, et al. The Role of Tumor Stroma in Cancer Progression and Prognosis: Emphasis on Carcinoma-Associated Fibroblasts and Non-small Cell Lung Cancer. J Thorac Oncol. 2011; 6: 209-217. PubMed: https://pubmed.ncbi.nlm.nih.gov/21107292/

Dvorak HF. Thrombosis and cancer. Hum Pathol. 1987; 18: 275–284.

Tempelhoff GFV, Heilmann L, Hommel G, Pollow K. Impact of Rheological variables in Cancer. Seminars in Thrombosis and Hemostasis. 2003; 29: 499-513. PubMed: https://pubmed.ncbi.nlm.nih.gov/14631550/

Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000; 83: 164–170. PubMed: https://pubmed.ncbi.nlm.nih.gov/10901365/

Caine GJ, Stonelake PS, Rea D, Lip GYH. Coagulopathic Complications in Breast Cancer. Cancer. 2003; 98: 1578-186. PubMed: https://pubmed.ncbi.nlm.nih.gov/14534872/

Bleker SM, Van Es N, Van Gills L, Daams JG, Kleinjan A, et al. Clinical course of upper extremity deep vein thrombosis in patients with or without cancer: a systematic review. Thrombo Res. 2016; 140: S81-S88. PubMed: https://pubmed.ncbi.nlm.nih.gov/27067985/

Tas F, Kilic L, Duranyildiz D. Coagulation tests show significant differences in patients with breast cancer. Tumor Biol. 2014; 35: 5985-5992. PubMed: https://pubmed.ncbi.nlm.nih.gov/24596033/

Prandoni P, Cornwali M, Marchiori A. Subcutaneous Adjusted-Dose Unfractionated Heparin vs Fixed-Dose Low-Molecular-Weight Heparinin the Initial Treatment of Venous Thromboembolism. Arch Interna Med. 2004; 164: 1077-1083. PubMed: https://pubmed.ncbi.nlm.nih.gov/15159264/

Wang Hui, Xu X, Pu C, Li L. Clinical characteristics and prognosis of cancer patients with venous thromboembolism. J Cancer Res Therapeut. 2019; 15: 344-349. PubMed: https://pubmed.ncbi.nlm.nih.gov/30964109/

Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost. 2007; 33: 688-694. PubMed: https://pubmed.ncbi.nlm.nih.gov/18000796/

Beleva E, Popov V, Popova JG. Hemostatic System in Malignancy: Providing the “Soil” in Metastatic Niche Formation, Tumor Metastasis, Ke Xu, IntechOpen. 2016. https://www.intechopen.com/books/tumor-metastasis/hemostatic-system-in-malignancy-providing-the-soil-in-metastatic-niche-formation

Kirwan CC, McDowell G, McCollum CN, Kumar S, Byrne GJ. Early changes in the hemostatic and procoagulant systems after chemotherapy for breast cancer. Br J Cancer. 2008; 99: 1000–1006. PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2567096/

Batschauer APB, Figueiredo CP, Bueno EC, Ribeiro MA, Dusse LMS, et al. D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. Ann Oncol. 2010; 21: 1267–272. PubMed: https://pubmed.ncbi.nlm.nih.gov/19880435/